동물 모델 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 구성 요소, 용도, 프로세스, 최종 사용자, 솔루션, 단계

The global Animal Model Market is projected to grow from $2.6 billion in 2025 to $5.6 billion by 2035, at a compound annual growth rate (CAGR) of 8.0%. The animal model market continues to expand alongside global biomedical research spending and increasing preclinical development activities. According to the National Institutes of Health (NIH), annual U.S. biomedical research funding exceeds USD 47 billion, supporting extensive use of laboratory animal models. The Organisation for Economic Co-operation and Development (OECD) reports sustained growth in biotechnology research investments among member countries, while the U.S. Food and Drug Administration (FDA) continues to require robust preclinical safety and efficacy data before clinical trials. Industry assessments indicate the global animal model market is projected to register a high single-digit CAGR through the forecast period, supported by rising gene-editing applications and increasing demand for personalized disease models.

Service offerings in the animal model market encompass breeding, cryopreservation, re-derivation, and quarantine programs that ensure the availability, genetic integrity, and health status of laboratory animals. Breeding services provide standardized colonies for research continuity, while cryopreservation secures valuable strains through embryo and sperm banking for long-term preservation. Re-derivation techniques eliminate pathogens using embryo transfer or cesarean methods, improving colony quality and reproducibility. Quarantine services prevent contamination and maintain biosecurity during animal importation and colony expansion. Rising demand for pathogen-free, genetically defined, and reproducible animal models is driving continuous investment in specialized laboratory animal service infrastructure worldwide.

Technology segmentation includes CRISPR, TALENs, Zinc Finger Nucleases, and RNA Interference, each enabling precise genetic manipulation for disease modeling and therapeutic research. CRISPR dominates due to its efficiency, scalability, and cost-effectiveness in generating knockout and knock-in animal models. TALENs and Zinc Finger Nucleases remain valuable for targeted genome editing requiring high specificity, while RNA Interference supports transient gene silencing for functional genomics studies. These technologies accelerate biomarker discovery, precision medicine development, and target validation. Continued innovation in genome editing platforms and expanding translational research programs are expected to strengthen technology adoption across research institutions and pharmaceutical companies.

Geographical Overview

North America maintains a leading position in the animal model market due to its extensive biomedical research infrastructure, well-established pharmaceutical industry, and substantial public and private R&D investments. The region benefits from advanced laboratory animal facilities, specialized breeding centers, and widespread adoption of genetically engineered models across academic institutions, biotechnology companies, and contract research organizations. Regulatory oversight from agencies such as the FDA and strong funding support from the NIH encourage continuous innovation in disease modeling and preclinical testing. Mature biotechnology ecosystems, experienced research personnel, and high demand for precision medicine further reinforce the region's market leadership.

Asia-Pacific continues to strengthen its position through expanding biotechnology capabilities, increasing pharmaceutical manufacturing, and substantial investments in life sciences research. Countries including China, Japan, South Korea, and India are enhancing laboratory infrastructure, establishing advanced animal research centers, and encouraging genome-editing research through supportive national innovation initiatives. Growing contract research activities, rising academic collaborations, and increasing clinical development programs are accelerating the adoption of animal models throughout the region. Continuous expansion of domestic biotechnology industries, improved research funding, and greater emphasis on translational medicine create favorable long-term opportunities for market participants.

Key Trends and Drivers

Technological Advancements in Genetic Engineering:

The animal model market is experiencing significant growth due to advancements in genetic engineering technologies such as CRISPR-Cas9. These technologies allow for precise modifications in animal genomes, facilitating the development of more accurate and reliable models for human diseases. This trend is driving research and development initiatives, enabling scientists to create models that closely mimic human physiological and pathological conditions, thereby enhancing the translational value of preclinical studies.

Rising Preclinical Research Investments Fuel Demand for Advanced Animal Models:

Growing investment in drug discovery, biologics development, and precision medicine is driving demand for advanced animal models capable of accurately replicating human diseases. Pharmaceutical and biotechnology companies increasingly rely on genetically modified animal models to improve target validation, efficacy assessment, and safety evaluation before clinical trials. Expanding research into oncology, rare diseases, neurological disorders, and immunology, combined with rising government funding for biomedical research, continues to support sustained market growth across developed and emerging economies.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Solutions
• 2.10 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Rodents
  • 4.1.2 Canines
  • 4.1.3 Felines
  • 4.1.4 Non-human Primates
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Animal Models
  • 4.2.2 Reagents and Consumables
  • 4.2.3 Instruments
  • 4.2.4 Software
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Breeding
  • 4.3.2 Quarantine
  • 4.3.3 Cryopreservation
  • 4.3.4 Genetic Testing
  • 4.3.5 Surgical Services
  • 4.3.6 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 CRISPR
  • 4.4.2 RNAi
  • 4.4.3 Microinjection
  • 4.4.4 Nuclear Transfer
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Drug Discovery
  • 4.5.2 Basic Research
  • 4.5.3 Toxicology
  • 4.5.4 Genetic Research
  • 4.5.5 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Research Institutes
  • 4.6.4 Contract Research Organizations
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 In Vivo
  • 4.7.2 In Vitro
  • 4.7.3 Ex Vivo
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Transgenic
  • 4.8.2 Knockout
  • 4.8.3 Knock-in
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Custom Animal Models
  • 4.9.2 Standard Animal Models
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Stage (2020-2035)
  • 4.10.1 Preclinical
  • 4.10.2 Clinical
  • 4.10.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Process
    • 5.2.1.9 Solutions
    • 5.2.1.10 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Process
    • 5.2.2.9 Solutions
    • 5.2.2.10 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Process
    • 5.2.3.9 Solutions
    • 5.2.3.10 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Process
    • 5.3.1.9 Solutions
    • 5.3.1.10 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Process
    • 5.3.2.9 Solutions
    • 5.3.2.10 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Process
    • 5.3.3.9 Solutions
    • 5.3.3.10 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Process
    • 5.4.1.9 Solutions
    • 5.4.1.10 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Process
    • 5.4.2.9 Solutions
    • 5.4.2.10 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Process
    • 5.4.3.9 Solutions
    • 5.4.3.10 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Process
    • 5.4.4.9 Solutions
    • 5.4.4.10 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Process
    • 5.4.5.9 Solutions
    • 5.4.5.10 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Process
    • 5.4.6.9 Solutions
    • 5.4.6.10 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Process
    • 5.4.7.9 Solutions
    • 5.4.7.10 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Process
    • 5.5.1.9 Solutions
    • 5.5.1.10 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Process
    • 5.5.2.9 Solutions
    • 5.5.2.10 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Process
    • 5.5.3.9 Solutions
    • 5.5.3.10 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Process
    • 5.5.4.9 Solutions
    • 5.5.4.10 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Process
    • 5.5.5.9 Solutions
    • 5.5.5.10 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Process
    • 5.5.6.9 Solutions
    • 5.5.6.10 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Process
    • 5.6.1.9 Solutions
    • 5.6.1.10 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Process
    • 5.6.2.9 Solutions
    • 5.6.2.10 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Process
    • 5.6.3.9 Solutions
    • 5.6.3.10 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Process
    • 5.6.4.9 Solutions
    • 5.6.4.10 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Process
    • 5.6.5.9 Solutions
    • 5.6.5.10 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Charles River Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 The Jackson Laboratory
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Taconic Biosciences
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Envigo
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Harlan Laboratories
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 GenOway
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Horizon Discovery Group
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 TransGenic Inc
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Crown Bioscience
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Pharmaron
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Biocytogen
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Cyagen Biosciences
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Janvier Labs
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Ozgene
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Ingenious Targeting Laboratory
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 SAGE Labs
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Creative Animodel
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Shanghai Model Organisms Center
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Biomere
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 InVivo Biosystems
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us